标题:Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects
作者:Hu, Yuan; Tian, Zhigang; Zhang, Cai
作者机构:[Hu, Yuan; Zhang, Cai] Shandong Univ, Sch Pharmaceut Sci, Inst Immunopharmacol & Immunotherapy, Jinan 250012, Shandong, Peoples R China.; [Tian, Zhi 更多
通讯作者:Tian, Zhigang;Zhang, C;Tian, ZG
通讯作者地址:[Zhang, C]Shandong Univ, Sch Pharmaceut Sci, Inst Immunopharmacol & Immunotherapy, Jinan 250012, Shandong, Peoples R China;[Tian, ZG]Univ Sci & Techno 更多
来源:ENGINEERING
出版年:2019
卷:5
期:1
页码:106-114
DOI:10.1016/j.eng.2018.11.015
关键词:Natural killer cell; Immunotherapy; Cancer; Clinical trial; Chimeric; antigen receptor
摘要:Natural killer (NK) cells are key innate immune cells that provide the first line of defense against viral infection and cancer. Although NK cells can discriminate between "self" and "non-self," recognize abnormal cells, and eliminate transformed cells and malignancies in real time, tumors develop several strategies to escape from NK cell attack. These strategies include upregulating ligands for the inhibitory receptors of NK cells and producing soluble molecules or immunosuppressive factors. Various types of NK cells are currently being applied in clinical trials, including autologous or allogeneic NK cells, umbilical cord blood (UCB) or induced pluripotent stem cell (iPSC)-derived NK cells, memory-like NK cells, and NK cell line NK-92 cells, for the treatment of different types of tumors. Chimeric antigen receptors (CARs)-NK cells have recently shown great potential due to their redirect specificity and effective antitumor activity. In this review, we summarize the mechanisms of tumor escape from NK cell recognition, the current status and advanced progress of NK cell-based immunotherapy, ways of enhancing the antitumor capacity of NK cells in vivo, and major challenges for clinical practice in this field. (C) 2019 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
收录类别:EI;SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060956947&doi=10.1016%2fj.eng.2018.11.015&partnerID=40&md5=6106546f714a427da228c82487cb58f0
TOP